

Shalabh Gupta, M.D.

Founder, Chairman, President & Chief Executive Officer, Unicycive Therapeutics, Inc. (Nasdaq: UNCY)



Shalabh Gupta, M.D. is the Founder, Chairman, President, and Chief Executive Officer of Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a U.S. biotechnology company focused on developing differentiated therapies for patients with kidney disease. A physician, biotech entrepreneur, former healthcare equity-research analyst, and commercial strategist, Dr. Gupta brings a rare end-to-end perspective on how life-sciences companies are conceived, financed, built, and brought to the public markets.

Dr. Gupta founded Unicycive in 2016 and has led its strategic evolution as a public-company CEO, including corporate formation, capital raising, pipeline development, investor engagement, business development, and the execution of a focused renal-disease strategy. His experience combines clinical medicine with the practical disciplines that determine whether innovation reaches patients: asset selection, development planning, regulatory strategy, commercial positioning, partnership formation, and access to growth capital.

Before founding Unicycive, Dr. Gupta held commercial-strategy roles at Genentech and worked as a healthcare equity-research analyst at UBS Investment Bank and Rodman & Renshaw. He also founded BioCycive and Globavir, and has served in advisory capacities for organizations including Synageva BioPharma, NYU Langone Medical Center's Office of Technology Transfer, the UCSF Innovation Center, and Stanford University School of Medicine's SPARK program. His career has therefore spanned academic and clinical innovation, venture creation, pharmaceutical commercialization, Wall Street investor communications, and public-company leadership.

Dr. Gupta is particularly interested in the policy and business frameworks that can make biomedical innovation more efficient, capital-efficient, and accessible to patients. In the United States, he has developed practical insight into the potential role of the FDA's 505(b)(2) regulatory pathway in enabling the development of differentiated medicines based on known active ingredients, where an appropriate scientific, regulatory, clinical, and commercial rationale exists. He welcomes dialogue with Japanese policymakers, regulators, academic institutions, investors, and industry leaders on how regulatory

modernization, translational execution, and access to capital can work together to strengthen biotechnology ecosystems.

As an active biotech entrepreneur and business-development leader, Dr. Gupta is also interested in evaluating and licensing high-quality Japanese innovation for global development and commercialization. He welcomes introductions to Japanese biotechnology and pharmaceutical companies, university spinouts, technology-transfer offices, venture funds, and portfolio-company leaders working on clinically meaningful therapeutic programs, platform technologies, or assets with a clear path to global value creation.

Dr. Gupta trained as a physician and previously practiced as an attending physician at NYU Medical Center and served as clinical faculty at NYU School of Medicine. He earned an MPA in Health Care Finance and Management from New York University's Robert F. Wagner Graduate School of Public Service and received his MD from Jawaharlal Institute of Postgraduate Medical Education & Research in India.